Loading
Keep a running, well-documented list of cancer practices and approvals that were reversed by later evidence, so the pattern of mistakes is visible and teachable.
Medical reversals (for example high-dose chemotherapy with stem-cell rescue in breast cancer, several accelerated approvals later withdrawn, bevacizumab in breast cancer) are scattered across the literature. A curated registry with, for each reversal, the original evidence, the reversing trial, the time to reversal, the patients exposed, and the design features that allowed the error would inform regulators and teach trainees.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Accelerated approval, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
Shares A machine-readable taxonomy of why cancer drugs fail, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden, Knowledge reaches practice too slowly.
Shares Compliance with results reporting at ClinicalTrials.gov, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Failures are hidden.
Shares A machine-readable taxonomy of why cancer drugs fail, Compliance with results reporting at ClinicalTrials.gov, Failures are hidden.
Shares Compliance with results reporting at ClinicalTrials.gov, Failures are hidden, Knowledge reaches practice too slowly.
Shares A machine-readable taxonomy of why cancer drugs fail, Failures are hidden.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Failures are hidden.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.